These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17134795)

  • 21. Cell-mediated immunity after pertussis vaccination and after natural infection.
    Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M
    Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
    Weston W; Messier M; Friedland LR; Wu X; Howe B
    Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.
    Esposito S; Agliardi T; Giammanco A; Faldella G; Cascio A; Bosis S; Friscia O; Clerici M; Principi N
    Infect Immun; 2001 Jul; 69(7):4516-20. PubMed ID: 11401994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.
    Canthaboo C; Williams L; Xing DK; Corbel MJ
    Vaccine; 2000 Nov; 19(6):637-43. PubMed ID: 11090715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.
    Wood N; McIntyre P; Marshall H; Roberton D
    Pediatr Infect Dis J; 2010 Mar; 29(3):209-15. PubMed ID: 20009964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.
    Jahnmatz M; Ljungman M; Netterlid E; Jenmalm MC; Nilsson L; Thorstensson R
    Clin Vaccine Immunol; 2014 Sep; 21(9):1301-8. PubMed ID: 25008903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.
    Eskola J; Ward J; Dagan R; Goldblatt D; Zepp F; Siegrist CA
    Lancet; 1999 Dec; 354(9195):2063-8. PubMed ID: 10636384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
    Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR
    Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of DNA microcarriers for evaluation of mice splenocytes genes expression after immunization with pertussis vaccines and challenged with different B. pertussis strains].
    Gzyl A; Woyciechowska-Oczko M; Jarzab B; Augustynowicz E; Mosiej E; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):149-59. PubMed ID: 17929412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
    Langue J; Matisse N; Pacoret P; Undreiner F; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1406-14. PubMed ID: 15063563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acellular pertussis vaccines and the role of pertactin and fimbriae.
    Poolman JT; Hallander HO
    Expert Rev Vaccines; 2007 Feb; 6(1):47-56. PubMed ID: 17280478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
    Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.